Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. The Company's molecules, whose systemic exposure is severely restricted, target transporters and receptors, modulating the uptake of nutrients or inducing secretion of key hormones to produce a therapeutic benefit in patients. Its non-systemic products act from within the intestines to avoid potential side effects that could occur with systemic exposure.
Ardelyx lead product, RDX5791, a minimally-absorbed, orally administered NHE3 sodium transport inhibitor, is being developed both for constipation-predominant irritable bowel syndrome (IBS-C) and for prevention of excess dietary sodium absorption, a new treatment modality for high blood pressure. RDX5791 is in phase 2 for IBS-C and a dose-ranging/regimen study for inhibition of excess dietary sodium absorption. Ardelyx is also developing RDX002, a minimally-absorbed, orally administered NaP2b phosphate transport inhibitor for the inhibition of phosphate absorption in patients with chronic kidney disease, and RDX009, a minimally-absorbed, orally administered TGR5 agonist for the treatment of type 2 diabetes through direct induction of intestinal incretins such as GLP-1 and PYY. 

Company Growth (employees)
Fremont, US
Size (employees)
93 (est)+53%
Ardelyx was founded in 2007 and is headquartered in Fremont, US

Ardelyx Office Locations

Ardelyx has an office in Fremont
Fremont, US (HQ)
34175 Ardenwood Blvd

Ardelyx Data and Metrics

Ardelyx Financial Metrics

Ardelyx's revenue was reported to be $24 m in FY, 2016

Revenue (FY, 2016)

24 m

Net income (FY, 2016)

(112.4 m)

EBIT (FY, 2016)

(112.9 m)

Market capitalization (20-Jul-2017)

260.6 m

Closing share price (20-Jul-2017)


Cash (31-Dec-2016)

74.6 m
Ardelyx's current market capitalization is $260.6 m.
USDFY, 2014FY, 2015FY, 2016


24 m24 m

R&D expense

94.2 m

General and administrative expense

18.7 m

Operating expense total

53.4 m112.9 m


(29.4 m)(112.9 m)

EBIT margin, %


Pre tax profit

(112.4 m)

Income tax expense

29 k

Net Income

(3.2 m)(29.6 m)(112.4 m)
USDFY, 2014FY, 2015FY, 2016


107.3 m107 m74.6 m

Accounts Receivable

2.6 m2.6 m


1.2 m5 m3.2 m

Current Assets

111.1 m112 m204 m


2.1 m4.7 m9 m

Total Assets

113.4 m116.9 m213.1 m

Accounts Payable

3.1 m2.8 m5.6 m

Current Liabilities

21.5 m7.7 m19.2 m

Total Liabilities

20 m

Additional Paid-in Capital

132.5 m210.4 m407.1 m

Retained Earnings

(71.9 m)(101.5 m)(213.9 m)

Total Equity

108.9 m193.2 m

Financial Leverage

1.1 x1.1 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(3.2 m)(29.6 m)(112.4 m)

Depreciation and Amortization

302 k829 k1.3 m

Accounts Receivable

3.9 m2.6 m2.6 m


(2.3 m)

Accounts Payable

831 k(371 k)2.1 m

Cash From Operating Activities

13.4 m(282 k)(92.5 m)

Purchases of PP&E

(1.9 m)(3.5 m)(4.9 m)

Cash From Investing Activities

(1.9 m)(3.5 m)(131.1 m)

Cash From Financing Activities

61.3 m75 m191.2 m

Income Taxes Paid

160 k69 k69 k
Y, 2016

Financial Leverage

1.1 x

Ardelyx Market Value History

Ardelyx Online and Social Media Presence

Ardelyx Company Life and Culture

You may also be interested in